Osteoarthritis Drugs Market (Drug Class - Corticosteroids, NSIADs and Others, Viscosupplementation Agents; Route of Administration - Oral, Parenteral, Topical; Distribution Channel - Hospital Pharmacies, Retail pharmacies, Online pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2030

Global Osteoarthritis Drugs Market- Snapshot

The global osteoarthritis drugs market is expected to reach a market value of about US$ 11,226.1 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Rise in R&D expenditure, increased prevalence of osteoarthritis across the globe, increased geriatric population, rise in awareness regarding degenerative bone diseases in developing countries, and rich pipeline of innovative treatment options are some factors that are expected to boost the global osteoarthritis drugs market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the global osteoarthritis drugs market during the forecast period. However, the high cost of advanced treatments and severe side-effects associated with certain injectable treatments are expected to hamper the osteoarthritis drugs market. 

The global osteoarthritis drugs market has been segmented based on drug class, route of administration, and distribution channel. In terms of drug class, the global market has been classified into corticosteroids, NSAIDs & others, and viscosupplementation agents. The viscosupplementation agents segment dominates the global osteoarthritis drugs market, in terms of value, owing to its high cost. This segment is also expected to expand at a significant CAGR owing to its effectiveness in the treatment of knee osteoarthritis, increasing acceptance of viscosupplementation for the treatment of chronic pain associated with osteoarthritis, and long duration of pain relief provided by the treatment. Based on route of administration, the global osteoarthritis drugs market has been divided into oral, parenteral, and topical. The parenteral segment held a major share of the market in 2017. It is expected to maintain its leading position, in terms of market share, during the forecast period.

In terms of distribution channel, the global osteoarthritis drugs market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a major share of the market in 2017, followed by retail pharmacies. The hospital pharmacies segment is expected to maintain its market share during forecast period due to acceptance of advanced treatment options requiring hospitalization. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of over-the-counter drugs at home at a discounted price.

In terms of geography, the global osteoarthritis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global osteoarthritis drugs market owing to high acceptance of viscosupplementation agents in the U.S. and presence of major players in the region. According to the Centers for Disease Control and Prevention, one in every five adults in the U.S. has doctor-diagnosed arthritis. As the country's population ages, it is estimated that this number would increase to at least 67% by 2030. Rising incidence of osteoarthritis leading to disability, demanding advanced therapies and disease modifying drugs, is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure, rising investments in research and development in countries such as China and India, and high acceptance of viscosupplementation agents in Japan. Furthermore, Japan is the second-largest market for viscosupplementation products after the U.S., which in turn is anticipated to further boost the market in Asia Pacific in the near future.

Major players operating in the global osteoarthritis drugs market include Horizon Pharma plc., Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc., Chugai Pharmaceutical Co., Limited, Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.

Osteoarthritis Drugs Market to Rise Remarkably Owing to Increasing Adoption of 3D Printing Technique

Ascend in R&D consumption, expanded commonness of osteoarthritis across the globe, expanded geriatric populace, ascend in mindfulness in regards to degenerative bone illnesses in agricultural nations, and rich pipeline of creative treatment alternatives are a few factors that are relied upon to help the worldwide osteoarthritis drugs market during the conjecture time frame. Additionally, expanding innovative work exercises in sickness changing medications and flood in venture by central participants in the clinical investigations of cutting edge therapy choices are relied upon to impel the worldwide osteoarthritis drugs market during the conjecture time frame. Be that as it may, the significant expense of cutting edge medicines and serious results related with certain injectable medicines are required to hamper the osteoarthritis drugs market.

The developing attention to sicknesses like degenerative bone illness, expanding R&D, and developing geriatric populace are the excellent elements enlarging development of the market. The drug business is developing through an intense stage as a few key licenses have terminated. Then again, the business is additionally confronted with freedoms to decrease fabricating costs impressively, because of headways like 3D printing, a few rewarding reevaluating openings, and possibilities like Nano innovation. This is required to go about as an impetus for advancement in the business with a few firms previously increasing current standards with new medication improvements and crucial adjustments in measures.

Osteoarthritis (OA) is a pervasive sickness all around the world and it influences the older populace harshly. The condition is likewise perilous to numerous as it prompts disabled versatility prompting more possible mishaps and monetary limitations. Be that as it may, the current yield of osteoarthritis drugs just offers torment alleviation and help, yet not a lasting arrangement. Moreover, osteoarthritis drugs likewise neglect to stop infection movement. Henceforth, notwithstanding their absence of adequacy and outrageous significant expenses of viscosupplementation, the worldwide osteoarthritis drugs market keeps on developing. Also, the rising older populace all throughout the planet, and expanding reach of projects like Medicare in the US and privatized medical care bill as of late presented in Australia, the osteoarthritis drugs market will bring about a few new chances for development.

The global osteoarthritis drugs market has been segmented as below:

by Drug Class

• Corticosteroids
• NSAIDs & Others
• Viscosupplementation Agents

by Route Of Administration

• Oral
• Parenteral
• Topical

by Distribution Channe

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

by Region

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• India
• China
• Japan
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• South Africa
• GCC Countries
• Rest of Middle East & Africa

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Osteoarthritis Drugs Market 

4. Market Overview
     4.1. Overview
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2016–2026
            4.4.1. Global Osteoarthritis Drugs Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1.Disease Prevalence & Incidence Rate globally with key countries
     5.2.Regulatory Scenario by Region/globally
     5.3.Pipeline Analysis

6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            6.3.1. Corticosteroids
            6.3.2. NSAIDs & others
            6.3.3. Viscosupplementation Agents 
     6.4. Global Osteoarthritis Drugs Market Attractiveness by Drug Class 

7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            7.3.1. Oral  
            7.3.2. Parenteral 
            7.3.3. Topical 
     7.4. Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration 

8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            8.3.1. Hospital pharmacies 
            8.3.2. Retail pharmacies 
            8.3.3. Online pharmacies 
     8.4. Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel 

9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Osteoarthritis Drugs Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
     9.3. Global Osteoarthritis Drugs Market Attractiveness, by Region

10. North America Osteoarthritis Drugs Market Analysis and Forecast
     10.1. Introduction
     10.2. North America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            10.2.1.Corticosteroids
            10.2.2. NSAIDs & Others
            10.2.3.Viscosupplementation agents 
     10.3. North America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            10.3.1. Oral  
            10.3.2. Parenteral 
            10.3.3. Topical 
     10.4. North America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            10.4.1. Hospital pharmacies 
            10.4.2. Retail pharmacies 
            10.4.3. Online pharmacies 
     10.5. North America Osteoarthritis Drugs Market Value Forecast, by Country, 2016–2026
            10.5.1. US
            10.5.2. Canada 
     10.6. North America Osteoarthritis Drugs Market Attractiveness Analysis 
            10.6.1. By Drug Class 
            10.6.2. By Route of Administration 
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Europe Osteoarthritis Drugs Market Analysis and Forecast
     11.1.Introduction
     11.2. Europe Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            11.2.1. Corticosteroids
            11.2.2. NSAIDs & Others
            11.2.3. Viscosupplementation agents 
     11.3. Europe Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            11.3.1. Oral  
            11.3.2. Parenteral 
            11.3.3. Topical 
     11.4. Europe Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            11.4.1. Hospital pharmacies 
            11.4.2. Retail pharmacies 
            11.4.3. Online pharmacies 
     11.5. Europe Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. France
            11.5.3. U.K.
            11.5.4. Italy
            11.5.5. Spain
            11.5.6. Rest of Europe
     11.6. Europe Osteoarthritis Drugs Market Attractiveness Analysis 
            11.6.1. By Drug Class 
            11.6.2. By Route of Administration 
            11.6.3. By Distribution Channel 
            11.6.4. By Country/Sub-region

12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
     12.1.Introduction
     12.2. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            12.2.1. Corticosteroids
            12.2.2. NSAIDs & Others
            12.2.3. Viscosupplementation agents 
     12.3. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            12.3.1. Oral  
            12.3.2. Parenteral 
            12.3.3. Topical 
     12.4. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            12.4.1. Hospital pharmacies 
            12.4.2. Retail pharmacies 
            12.4.3. Online pharmacies 
     12.5. Asia Pacific Osteoarthritis Drugs Market Value Forecast by Country/Sub-region, 2016–2026
            12.5.1. Japan
            12.5.2. China
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis 
            12.6.1. By Drug Class 
            12.6.2. By Route of Administration 
            12.6.3. By Distribution Channel 
            12.6.4. By Country/Sub-region

13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
     13.1.Introduction
     13.2. Latin America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            13.2.1. Corticosteroids
            13.2.2. NSAIDs & Others
            13.2.3. Viscosupplementation agents 
     13.3. Latin America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            13.3.1. Oral  
            13.3.2. Parenteral 
            13.3.3. Topical 
     13.4. Latin America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            13.4.1. Hospital pharmacies 
            13.4.2. Retail pharmacies 
            13.4.3. Online pharmacies 
     13.5. Latin America Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Osteoarthritis Drugs Market Attractiveness Analysis 
            13.6.1. By Drug Class 
            13.6.2. By Route of Administration 
            13.6.3. By Distribution Channel 
            13.6.4. By Country/Sub-region

14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
     14.1.Introduction
     14.2. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            14.2.1. Corticosteroids
            14.2.2. NSAIDs & Others
            14.2.3. Viscosupplementation agents 
     14.3. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            14.3.1. Oral  
            14.3.2. Parenteral 
            14.3.3. Topical 
     14.4. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            14.4.1. Hospital pharmacies 
            14.4.2. Retail pharmacies 
            14.4.3. Online pharmacies 
     14.5. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Country/Sub-regions, 2016–2026
            14.5.1. GCC Countries
            14.5.2. Israel
            14.5.3. South Africa
            14.5.4. Rest of MEA
     14.6. Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis 
            14.6.1. By Drug Class 
            14.6.2. By Route of Administration 
            14.6.3. By Distribution Channel 
            14.6.4. By Country

15. Competition Landscape
     15.1. Global Osteoarthritis Drugs Market Player – Competition Matrix (by Tier and Size of companies)
     15.2. Global Osteoarthritis Drugs Market Share Analysis, by Company (2016)
     15.3. Company Profiles
            15.3.1. Horizon Pharma plc. 
                     15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.1.2. Product Portfolio
                     15.3.1.3. SWOT Analysis
                     15.3.1.4. Financial Overview
                     15.3.1.5. Strategic Overview
            15.3.2. Pfizer Inc.
                     15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.2.2. Product Portfolio
                     15.3.2.3. SWOT Analysis
                     15.3.2.4. Financial Overview
                     15.3.2.5. Strategic Overview
            15.3.3. Sanofi 
                     15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.3.2. Product Portfolio
                     15.3.3.3. SWOT Analysis
                     15.3.3.4. Financial Overview
                     15.3.3.5. Strategic Overview
            15.3.4. Anika Therapeutics, Inc.  
                     15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.4.2. Product Portfolio
                     15.3.4.3. SWOT Analysis
                     15.3.4.4. Financial Overview
                     15.3.4.5. Strategic Overview
            15.3.5. Ferring B.V.
                     15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.5.2. Product Portfolio
                     15.3.5.3. SWOT Analysis
                     15.3.5.4. Financial Overview
                     15.3.5.5. Strategic Overview
            15.3.6. Bioventus, Inc. 
                     15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.6.2. Product Portfolio
                     15.3.6.3. SWOT Analysis
                     15.3.6.4. Financial Overview
                     15.3.6.5. Strategic Overview
            15.3.7. Chugai Pharmaceutical Industries Limited  
                     15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.7.2. Product Portfolio
                     15.3.7.3. SWOT Analysis
                     15.3.7.4. Financial Overview
                     15.3.7.5. Strategic Overview
            15.3.8. Alkem Laboratories
                     15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.8.2. Product Portfolio
                     15.3.8.3. SWOT Analysis
                     15.3.8.4. Financial Overview
                     15.3.8.5. Strategic Overview
            15.3.9. Flexion Therapeutics, Inc.  
                     15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.9.2. Product Portfolio
                     15.3.9.3. SWOT Analysis
                     15.3.9.4. Financial Overview
                     15.3.9.5. Strategic Overview
            15.3.10. Zimmer Biomet Holdings, Inc.
                     15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.10.2. Product Portfolio
                     15.3.10.3. SWOT Analysis
                     15.3.10.4. Financial Overview
                     15.3.10.5. Strategic Overview